MAGI3-AKT3 fusion in breast cancer amended

Nature

Volumn 520, Issue 7547, 2015, Pages E11-E12

  Mosquera, Juan Miguel ^a,b   Varma, Sonal ^a   Pauli, Chantal ^a,b,c   MacDonald, Theresa Y ^a   Yashinskie, Jossie J ^a   Varga, Zsuzsanna ^c   Sboner, Andrea ^a,b   Moch, Holger ^c   Rubin, Mark A ^a,b   Shin, Sandra J ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HYBRID PROTEIN; MAGI3 AKT3 FUSION PROTEIN; PROGESTERONE RECEPTOR; UNCLASSIFIED DRUG;

CANCER; DISEASE TREATMENT; GENE EXPRESSION; GENETIC ANALYSIS; METABOLISM; TUMOR;

ADULT; AGED; ARTICLE; FEMALE; GENE FREQUENCY; GENE REARRANGEMENT; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRIPLE NEGATIVE BREAST CANCER; BREAST TUMOR; CLASSIFICATION; GENE TRANSLOCATION; GENETICS; MUTATION;

BREAST NEOPLASMS; FEMALE; HUMANS; MUTATION; TRANSLOCATION, GENETIC;

EID: 84928386564     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature14265     Document Type: Article

References (13)

1. Banerji, S. et al. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 486, 405-409 (2012).
2. Bauer, K. R., Brown, M., Cress, R. D., Parise, C. A. & Caggiano, V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry. Cancer 109, 1721-1728 (2007).
3. Pal, S. K., Childs, B. H. & Pegram, M. Triple negative breast cancer: unmet medical needs. Breast Cancer Res. Treat. 125, 627-636 (2011).
4. Craig, D. W. et al. Genome and transcriptome sequencing in prospective refractory metastatic triple negative breast cancer uncovers therapeutic vulnerabilities. Mol. Cancer Ther. 12, 104-116 (2013).
5. Robinson, D. R. et al. Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer. Nature Med. 17, 1646-1651 (2011).
6. Berger, M. F. et al. The genomic complexity of primary human prostate cancer. Nature 470, 214-220 (2011).
7. Perner, S. et al. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res. 66, 8337-8341 (2006).
8. Tomlins, S. A. et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310, 644-648 (2005).
9. Sboner, A. et al. FusionSeq: a modular framework for finding gene fusions by analyzing paired-end RNA-sequencing data. Genome Biol. 11, R104 (2010).
10. Pflueger, D. et al. Discovery of non-ETS gene fusions in human prostate cancer using next-generation RNA sequencing. Genome Res. 21, 56-67 (2011).
11. Mosquera, J. M. et al. Recurrent NCOA2 gene rearrangements in congenital/infantile spindle cell rhabdomyosarcoma. Genes Chromosom. Cancer 52, 538-550 (2013).
12. Mosquera, J. M. et al. Novel miR143-NOTCH fusions in benign and malignant glomus tumors. Genes Chromosom. Cancer 52, 1075-1087 (2013).
13. Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15-21 (2013).